Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein

New England Journal of Medicine

Volumn 334, Issue 26, 1996, Pages 1697-1702

  Fisher Jr , Charles J ^a   Agosti, Jan M ^b   Opal, Steven M ^c   Lowry, Stephen F ^d   Balk, Robert A ^e   Sadoff, Jerald C ^f   Abraham, Edward ^g   Schein, Roland M H ^h   Benjamin, Ernest ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c BROWN UNIVERSITY   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INTERLEUKIN 6; PLACEBO; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BACTEREMIA; CHO CELL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOTOXEMIA; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 0029900294     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606273342603     Document Type: Article

References (57)

1. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: valid clinical entity. Crit Care Med 1989;17:389-93.
2. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990;39:31-4.
3. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318: 1481-6.
4. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
5. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
6. Tracey KJ, Lowry SF, Fahey TJ III, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987;164:415-22.
7. Bauss F, Droge W, Mannel DN. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 1987;55:1622-5.
8. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-7.
9. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6:1328-34.
10. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
11. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330: 662-4.
12. Opal SM, Cross AS, Kelley NM, et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1990;161:1148-52.
13. Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gramnegative shock. J Infect Dis 1990;162:421-7.
14. I(N) septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990;30:279-92.
15. Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 1992;127:138-45.
16. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264: 11974-80.
17. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270-5.
18. Schutze S, Scheurich P, Pfizenmaier K, Kronke M. Tumor necrosis factor signal transduction: tissue-specific serine phosphorylation of a 26-kDa cytosolic protein. J Biol Chem 1989;264:3562-7.
19. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;266:7313-6.
20. Gatanaga T, Hwang CD, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultraliltrates of human cancer patients. Proc Natl Acad Sci U S A 1990;87:8781-4.
21. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988;167:1511-6.
22. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
23. Girardin E, Grau GE, Dayer J-M, Roux-Lombard P, the J5 Study Group, Lambert P-H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988;319:397-400.
24. Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17:489-94.
25. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.
26. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/tumor necrosis fuctor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990;170:32-8.
27. Marks JD, Marks CB, Luce JM, et al. Plasma tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 1990;141:94-7.
28. Offner F, Philippe J, Vogelaers D, et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116:100-5.
29. Culandra T, Baumgartner JD, Grau GB, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990;161: 982-7.
30. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer J-M. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcemia. Immunology 1992;76:20-3.
31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimentl and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo. Proc Natl Acad Sci U S A 1992;89:4845-9.
32. Mohler KM, Torrance DS, Smith CA, et al, Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
33. Opal SM, Palardy JE, Romulo RLC, Cross AS, Rousfeau A-M, Widmer M. Tumor necrosis factor receptor-Fc fusion protein (sTNFR:Fc) in the treatment of experimental Pseudomonas sepsis. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 17-20, 1993. Washington, D.C.: American Society for Microbiology, 1993:379, abstract.
34. MacVittie T, Kittell C, Kirschner K, Agosti J, Williams D, Widmer M. Effect of soluble rhu IL-1 and TNF receptors on hemodynamics, metabolism, hematology and circulating levels of inflammatory cytokines in a nonhuman primate model of endotoxin shock. In: Proceedings. Second Conference of the International Endotoxin Society. Vienna, Austria, August 17-20, 1992: 229. abstract.
35. Evans T, Carpenter A, Martin R, Cohen J. Protective effect of soluble tumor necrosis factor receptor in experimental gram-negative sepsis. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. October 17-20, 1993. Washington, D.C.: American Society for Microbiology, 1993:378. abstract.
36. Suffredini AF, Reda D, Agosti J, Banks S. Cardiovascular and cytokine responses of normal humans following intravenous endotoxin and recombinant human tumor necrosis factor receptor (TNFR:Fc). Intensive Care Med 1994;20:Suppl 1:S147. abstract.
37. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults, Chest 1991;100:1619-36.
38. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Crit Care Med 1992;20:864-74.
39. Ziegler BJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
40. Fisher CJ Jr, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27.
41. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
42. Suitters AJ, Foulkes R, Opal SM, et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med 1994;179:849-56.
43. Baumgartner S, Morland LW, Schiff MH, et al. Double-blind, placebo-controlled trial of tumor necrosis factor receptor fusion protein (TNFR: Fc) in active rheumatoid arthritis. Presented at Biomedicine '96: Medical Research from Bench to Bedside, Washington, D.C., May 3-6, 1996. abstract.
44. Evans TJ, Moycs D, Carpenter A, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis, J Exp Med 1994;180: 2173-9.
45. Mastroeni P, Arena A, Costa GB, Liberto MC, Bonina L, Hormueche CE. Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies. Microb Pathog 1991;11:33-8.
46. van Furth R, van Zwet TL, Buisman AM, van Dissel JT. Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J Infect Dis 1994;170:234-7.
47. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB. Type 1 IL-I receptor blockade exacerbates murine listeriosis. J Immunol 1992;148: 1486-92.
48. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991;163:83-8.
49. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992;148: 2724-30.
50. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin-1 alpha protects mice from lethal bacterial infection. J Exp Med 1989;169:2021-7.
51. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A 1991;88:10535-9.
52. Jin H, Yang R, Marsters SA, et al. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J Infect Dis 1994;170:1323-6.
53. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
54. Carlet J, Cohen J, Andersson J, et al. INTERSEPT: an international efficacy and safety study of monoclonal antibody (MAb) to human tumor necrosis factor (hTNF) in patients with the sepsis syndrome. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. Fla., October 4-7, 1994. Washington, D.C.: American Society for Microbiology, 1994:7. abstract.
55. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720-8.
56. Tenaillon A, Dhainaut JF, Hemmer M, et al. Confirming phase III clinical trial to study the efficacy of a P.A.F. antagonist, BN 52021, in reducing mortality of patients with severe gram-negative sepsis. In: Proceedings, First Autumnal International Meeting on Sepsis. Deauville, France, November 7-8. 1994:31. abstract.
57. Fisher CJ Jr. Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.